Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort

      Highlights

      • In the GRADE cohort prevalence of diabetes-related complications at baseline ranged from 7-21%.
      • These complications overall exhibited expected relationships with non-glycemic risk factors.
      • Expected relationships with glycemia were not seen, likely owing to study enrollment criteria.
      • These observations provide a baseline for observations of randomized treatment effects.

      Abstract

      Aims

      The Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) trial is a randomized clinical trial comparing glycemic effects of four diabetes medications added to metformin in type 2 diabetes (T2D). Microvascular and macrovascular diseases are secondary outcomes. We evaluated the prevalence and risk factor relationships for microvascular and macrovascular complications in the GRADE cohort at study entry.

      Methods

      Complication prevalence and risk factors were analyzed based on data from screening in all consenting participants meeting GRADE eligibility. Logistic regression and Z-statistics were used to assess risk factor relationships with complications.

      Results

      We enrolled 5047 T2D participants [mean age 57 years; 36% female; mean known T2D duration 4 years (all < 10 years); mean HbA1c 8.0% (∼64 mmol/mol) at screening]. Urinary albumin/creatinine ratio (ACR) ≥ 30 mg/gram was present in 15.9% participants; peripheral neuropathy (by Michigan Neuropathy Screening Instrument) in 21.5%; cardiovascular autonomic neuropathy by electrocardiography-derived indices in 9.7%; self-reported retinopathy in 1.0%. Myocardial infarction ascertained by self-report or electrocardiogram was present in 7.3%, and self-reported history of stroke in 2.0%.

      Conclusions

      In the GRADE cohort with < 10 years of T2D and a mean HbA1c of 8.0%, diabetes complications were present in a substantial fraction of participants, more so than might otherwise have been expected.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Pop-Busui R.
        • Boulton A.J.
        • Feldman E.L.
        • Bril V.
        • Freeman R.
        • Malik R.A.
        • et al.
        Diabetic neuropathy: a position statement by the american diabetes association.
        Diabetes Care. 2017; 40: 136-154
        • Solomon S.D.
        • Chew E.
        • Duh E.J.
        • Sobrin L.
        • Sun J.K.
        • VanderBeek B.L.
        • et al.
        Diabetic retinopathy: a position statement by the american diabetes association.
        Diabetes Care. 2017; 40: 412-418
        • Tuttle K.R.
        • Bakris G.L.
        • Bilous R.W.
        • Chiang J.L.
        • de Boer I.H.
        • Goldstein-Fuchs J.
        • et al.
        Diabetic kidney disease: a report from an ADA consensus conference.
        Diabetes Care. 2014; 37: 2864-2883
        • Brownrigg J.R.
        • Hughes C.O.
        • Burleigh D.
        • Karthikesalingam A.
        • Patterson B.O.
        • Holt P.J.
        • et al.
        Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study.
        Lancet Diabetes Endocrinol. 2016; 4: 588-597
        • Gregg E.W.
        • Sattar N.
        • Ali M.K.
        The changing face of diabetes complications.
        Lancet Diabetes Endocrinol. 2016; 4: 537-547
        • Boyle J.P.
        • Thompson T.J.
        • Gregg E.W.
        • Barker L.E.
        • Williamson D.F.
        Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.
        Popul Health Metr. 2010; 8: 29
        • Pop-Busui R.
        • Lu J.
        • Brooks M.M.
        • Albert S.
        • Althouse A.D.
        • Escobedo J.
        • et al.
        Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort.
        Diabetes Care. 2013; 36: 3208-3215
        • Lachin J.M.
        • Genuth S.
        • Nathan D.M.
        • Zinman B.
        • Rutledge B.N.
        DCCT/EDIC research group: effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial–revisited.
        Diabetes. 2008; 57: 995-1001
        • Buehler A.M.
        • Cavalcanti A.B.
        • Berwanger O.
        • Figueiro M.
        • Laranjeira L.N.
        • Zazula A.D.
        • et al.
        Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials.
        Cardiovasc Ther. 2013; 31: 147-160
      1. CONTROL Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR et al: Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52(11):2288-2298.

        • Khanam P.A.
        • Hoque S.
        • Begum T.
        • Habib S.H.
        • Latif Z.A.
        Microvascular complications and their associated risk factors in type 2 diabetes mellitus.
        Diabetes Metab Syndr. 2017; 11: S577-S581
        • Bjerg L.
        • Hulman A.
        • Carstensen B.
        • Charles M.
        • Jorgensen M.E.
        • Witte D.R.
        Development of microvascular complications and effect of concurrent risk factors in type 1 diabetes: a multistate model from an observational clinical cohort study.
        Diabetes Care. 2018; 41: 2297-2305
        • Perreault L.
        • Pan Q.
        • Aroda V.R.
        • Barrett-Connor E.
        • Dabelea D.
        • Dagogo-Jack S.
        • et al.
        Exploring residual risk for diabetes and microvascular disease in the diabetes prevention program outcomes study (DPPOS).
        Diabet Med. 2017;
        • Bebu I.
        • Braffett B.H.
        • Orchard T.J.
        • Lorenzi G.M.
        • Lachin J.M.
        DCCT/EDIC research group: mediation of the effect of glycemia on the risk of CVD Outcomes in type 1 diabetes: the DCCT/EDIC study.
        Diabetes Care. 2019; 42: 1284-1289
        • Nathan D.M.
        • Buse J.B.
        • Kahn S.E.
        • Krause-Steinrauf H.
        • Larkin M.E.
        • Staten M.
        • et al.
        GRADE study research group: rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
        Diabetes Care. 2013; 36: 2254-2261
        • Wexler D.J.
        • Krause-Steinrauf H.
        • Crandall J.P.
        • Florez H.J.
        • Hox S.H.
        • Kuhn A.
        • et al.
        Grade research group: baseline characteristics of randomized participants in the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
        Diabetes Care. 2019;
        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • Zhang Y.L.
        • Castro 3rd, A.F.
        • Feldman H.I.
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • American Diabetes Association
        11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019.
        Diabetes Care. 2019; 42: S124-S138
        • Herman W.H.
        • Pop-Busui R.
        • Braffett B.H.
        • Martin C.L.
        • Cleary P.A.
        • Albers J.W.
        • et al.
        DCCT/EDIC research group: use of the michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications.
        Diabet Med. 2012; 29: 937-944
        • Ismail-Beigi F.
        • Craven T.
        • Banerji M.A.
        • Basile J.
        • Calles J.
        • Cohen R.M.
        • et al.
        Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
        Lancet. 2010; 376: 419-430
        • O'Neal W.T.
        • Chen L.Y.
        • Nazarian S.
        • Soliman E.Z.
        Reference ranges for short-term heart rate variability measures in individuals free of cardiovascular disease: the multi-ethnic study of atherosclerosis (MESA).
        J Electrocardiol. 2016; 49: 686-690
        • Grundy S.M.
        • Brewer Jr., H.B.
        • Cleeman J.I.
        • Smith Jr., S.C.
        • Lenfant C.
        National heart lung and blood institute, american heart association: definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition.
        Arterioscler Thromb Vasc Biol. 2004; 24: e13-18
        • Arnett D.K.
        • Blumenthal R.S.
        • Albert M.A.
        • Buroker A.B.
        • Goldberger Z.D.
        • Hahn E.J.
        • et al.
        2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines.
        J Am Coll Cardiol. 2019;
        • Mullis P.
        • Kochli H.P.
        • Zuppinger K.
        • Schwarz H.P.
        Intermittent microalbuminuria in children with type 1 diabetes mellitus without clinical evidence of nephropathy.
        Eur J Pediatr. 1988; 147: 385-388
      2. Mason H, J., Stevenson A.J., Williman N., Morgan M: Intra individual variability in markers of proteinuria for normal subjects and those with cadmium induced renal dysfunction: interpretation of results from untimed, random urine samples. Biomarkers 1999, 4(2):118-128.

        • Diabetes Prevention Program Research Group
        Changes in albumin excretion in the diabetes prevention program.
        Diabetes Care. 2009; 32: 720-725
        • Mather K.J.
        • Pan Q.
        • Knowler W.C.
        • Funahashi T.
        • Bray G.A.
        • Arakaki R.
        • et al.
        Diabetes prevention program research group: treatment-induced changes in plasma adiponectin do not reduce urinary albumin excretion in the diabetes prevention program cohort.
        PLoS ONE. 2015; 10e0136853
        • Bakris G.
        • Viberti G.
        • Weston W.M.
        • Heise M.
        • Porter L.E.
        • Freed M.I.
        Rosiglitazone reduces urinary albumin excretion in type II diabetes.
        J Hum Hypertens. 2003; 17: 7-12
        • Cooper M.E.
        • Perkovic V.
        • McGill J.B.
        • Groop P.H.
        • Wanner C.
        • Rosenstock J.
        • et al.
        Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes.
        Am J Kidney Dis. 2015; 66: 441-449
        • Bakris G.L.
        • Toto R.D.
        • McCullough P.A.
        • Rocha R.
        • Purkayastha D.
        • Davis P.
        Guard study investigators: effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
        Kidney Int. 2008; 73: 1303-1309
        • Wanner C.
        • Inzucchi S.E.
        • Lachin J.M.
        • Fitchett D.
        • von Eynatten M.
        • Mattheus M.
        • et al.
        Empagliflozin and progression of kidney disease in Type 2 diabetes.
        N Engl J Med. 2016;
        • O'Connor P.J.
        • Ismail-Beigi F.
        Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE.
        Ther Adv Endocrinol Metab. 2011; 2: 17-26
        • Andersen S.T.
        • Witte D.R.
        • Dalsgaard E.M.
        • Andersen H.
        • Nawroth P.
        • Fleming T.
        • et al.
        Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark.
        Diabetes Care. 2018; 41: 1068-1075
        • Franklin G.M.
        • Kahn L.B.
        • Baxter J.
        • Marshall J.A.
        Hamman RF: sensory neuropathy in non-insulin-dependent diabetes mellitus. The san luis valley diabetes study.
        Am J Epidemiol. 1990; 131: 633-643
        • Ziegler D.
        • Rathmann W.
        • Dickhaus T.
        • Meisinger C.
        • Mielck A.
        Kora study group: prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA augsburg surveys S2 and S3.
        Diabetes Care. 2008; 31: 464-469
        • Callaghan B.C.
        • Xia R.
        • Reynolds E.
        • Banerjee M.
        • Rothberg A.E.
        • Burant C.F.
        • et al.
        Association between metabolic syndrome components and polyneuropathy in an obese population.
        JAMA Neurol. 2016; 73: 1468-1476
        • Moon S.S.
        • Choi Y.K.
        • Seo H.A.
        • Jeon J.H.
        • Lee J.E.
        • Jeong J.Y.
        • et al.
        Relationship between cardiovascular autonomic neuropathy and coronary artery calcification in patients with type 2 diabetes.
        Endocr J. 2010; 57: 445-454
        • Konen J.C.
        • Summerson J.H.
        • Bell R.A.
        • Curtis L.G.
        Racial differences in symptoms and complications in adults with type 2 diabetes mellitus.
        Ethn Health. 1999; 4: 39-49
        • Winkley K.
        • Thomas S.M.
        • Sivaprasad S.
        • Chamley M.
        • Stahl D.
        • Ismail K.
        • et al.
        The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London Diabetes cohort (SOUL-D).
        Diabetologia. 2013; 56: 1272-1281
        • Tahrani A.A.
        • Altaf Q.A.
        • Piya M.K.
        • Barnett A.H.
        Peripheral and autonomic neuropathy in south asians and white caucasians with type 2 diabetes mellitus: possible explanations for epidemiological differences.
        J Diabetes Res. 2017; 2017: 1273789
        • Basu S.
        • Sussman J.B.
        • Berkowitz S.A.
        • Hayward R.A.
        • Yudkin J.S.
        Development and validation of risk equations for complications of type 2 Diabetes (RECODe) using individual participant data from randomised trials.
        Lancet Diab Endocrinol. 2017; 5: 788-798
        • Gaede P.
        • Oellgaard J.
        • Carstensen B.
        • Rossing P.
        • Lund-Andersen H.
        • Parving H.H.
        • et al.
        Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.
        Diabetologia. 2016; 59: 2298-2307
        • Grassi M.A.
        • Mazzulla D.A.
        • Knudtson M.D.
        • Huang W.W.
        • Lee K.E.
        • Klein B.E.
        • et al.
        Patient self-report of prior laser treatment reliably indicates presence of severe diabetic retinopathy.
        Am J Ophthalmol. 2009; 147: 501-504
        • Patty L.
        • Wu C.
        • Torres M.
        • Azen S.
        • Varma R.
        Los angeles latino eye study group: validity of self-reported eye disease and treatment in a population-based study: the los angeles latino eye study.
        Ophthalmology. 2012; 119: 1725-1730